SynthesisFrontiers in oncology2026
Endothelial-to-mesenchymal transition and vasculogenic mimicry in tumor vascular plasticity: a comparative bibliometric analysis and mechanistic framework.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endothelial-to-mesenchymal transition (EndMT) and vasculogenic mimicry (VM) are distinct forms of cellular and vascular plasticity that may contribute to tumor vascular adaptation. Although they have largely evolved as separate research fields, emerging experimental observations suggest potential convergence in their regulation by the tumor microenvironment. Methods: We performed a comparative bibliometric analysis of EndMT and VM using the Web of Science Core Collection and Scopus for publications from 2005 to 2025. After cross-database deduplication and retraction screening using a custom open-source data-fusion pipeline, 4,746 records were retained (2,056 EndMT; 2,695 VM).Publication trends, collaboration networks, keyword co-occurrence, thematic structures, and citation bursts were analyzed using bibliometrix/Biblioshiny, VOSviewer, and CiteSpace. Results: Only five publications explicitly addressed both EndMT and VM in an oncological context, indicating limited formal overlap between the two literatures. Nevertheless, keyword co-occurrence, citation-burst, and thematic analyses revealed convergent research interests involving the tumor microenvironment, cellular plasticity, extracellular-matrix remodeling, and therapeutic resistance. These patterns motivated a mechanistic synthesis centered on three potential points of convergence: shared upstream signaling involving TGF-β, hypoxia/HIF-1α, and context-dependent Notch activity; EndMT-associated stromal and extracellular-matrix remodeling that may facilitate VM; and partial or hybrid cellular states. Conclusions: EndMT and VM should be considered distinct but potentially interconnected components of tumor vascular plasticity rather than simple alternatives to conventional angiogenesis. The bibliometric convergence provides a rationale for investigating their potential interactions, but does not establish a causal or bidirectional relationship. We therefore propose a testable conceptual framework in which shared microenvironmental pressures may influence both processes, while EndMT-associated stromal remodeling may provide one potential route toward a VM-permissive niche. Spatial transcriptomics, lineage tracing, co-culture models, and organoid systems may help determine whether these interactions occur
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.